Zhongshan Ligao Biopharmaceutical

Ligao Biopharmaceutical is a clinical-stage biotechnology company headquartered in Zhongshan, China, dedicated to the discovery and development of long-acting protein and peptide drugs. The company leverages its proprietary site-specific modification technology platform to create innovative biologics with improved stability and extended half-lives. Its primary therapeutic focus includes metabolic diseases such as type 2 diabetes and obesity, as well as NASH, oncology, and endocrine disorders. The lead program, LG001, is a long-acting GLP-1 receptor agonist currently in clinical development. Ligao Biopharmaceutical is backed by prominent venture capital firms, including Legend Capital and Qiming Venture Partners.